Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Onwipa Rochanathimoke, Arthorn Riewpaiboon, Naiyana Praditsitthikorn, Piyanit Tharmaphornpilas, Suchada Jiamsiri, Montarat Thavorncharoensap & Maarten J. Postma. (2021) Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 811-819.
Read now
Read now
A.D. Steele, J.C. Victor, M.E. Carey, J.E. Tate, D.E. Atherly, C. Pecenka, Z. Diaz, U.D. Parashar & C.D. Kirkwood. (2019) Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?. Human Vaccines & Immunotherapeutics 15:6, pages 1215-1227.
Read now
Read now
Zenas Kuate Defo & Byong Lee. (2016) New approaches in oral rotavirus vaccines. Critical Reviews in Microbiology 42:3, pages 495-505.
Read now
Read now
Sarah M Bartsch & Bruce Y Lee. (2014) Economics and financing of vaccines for diarrheal diseases. Human Vaccines & Immunotherapeutics 10:6, pages 1568-1581.
Read now
Read now
Samuel Aballéa, Aurélie Millier, Sibilia Quilici, Stuart Caroll, Stavros Petrou & Mondher Toumi. (2013) A critical literature review of health economic evaluations of rotavirus vaccination. Human Vaccines & Immunotherapeutics 9:6, pages 1272-1288.
Read now
Read now
Articles from other publishers (18)
Theodore H. Tulchinsky, Elena A. Varavikova & Matan J. Cohen. 2023. The New Public Health. The New Public Health
1037
1095
.
Reza Hashempour, Behzad Raei, Majid Safaei Lari, Nasrin Abolhasanbeigi Gallezan & Ali AkbariSari. (2021) QALY league table of Iran: a practical method for better resource allocation. Cost Effectiveness and Resource Allocation 19:1.
Crossref
Crossref
Mélanie Drolet, Élodie Bénard, Mark Jit, Raymond Hutubessy & Marc Brisson. (2018) Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. Value in Health 21:10, pages 1250-1258.
Crossref
Crossref
Tharani LoganathanChiu-Wan NgWay-Seah LeeRaymond C W HutubessyStéphane VerguetMark Jit. (2018) Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. Health Policy and Planning 33:2, pages 204-214.
Crossref
Crossref
Natalie Carvalho, Mark Jit, Sarah Cox, Joanne Yoong & Raymond C. W. Hutubessy. (2017) Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework. PharmacoEconomics 36:1, pages 79-90.
Crossref
Crossref
Asrul Akmal Shafie, Hui Yee Yeo, Laurent Coudeville, Lucas Steinberg, Balvinder Singh Gill, Rohani Jahis & Amar-Singh HSS. (2017) The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling. PharmacoEconomics 35:5, pages 575-589.
Crossref
Crossref
Shuhui Cui, Ruoyan Gai Tobe, Xiuting Mo, Xiaoyan Liu, Lingzhong Xu & Shixue Li. (2016) Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. BMC Infectious Diseases 16:1.
Crossref
Crossref
Joseph D. Njau & Lisa K. Cairns. (2016) A literature review on the economic benefits of vaccines in low and middle income countries: Evaluating progress in the era of ‘a decade of vaccines’ initiative. Vaccine Reports 6, pages 62-76.
Crossref
Crossref
Kittiphong Thiboonboon, Benjarin Santatiwongchai, Varit Chantarastapornchit, Waranya Rattanavipapong & Yot Teerawattananon. (2016) A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines. Applied Health Economics and Health Policy 14:6, pages 659-672.
Crossref
Crossref
Tharani Loganathan, Mark Jit, Raymond Hutubessy, Chiu-Wan Ng, Way-Seah Lee & Stéphane Verguet. (2016) Rotavirus vaccines contribute towards universal health coverage in a mixed public-private healthcare system. Tropical Medicine & International Health 21:11, pages 1458-1467.
Crossref
Crossref
A. T. Newall, M. Jit & R. Hutubessy. (2014) Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines. PharmacoEconomics 32:6, pages 525-531.
Crossref
Crossref
Lizell B. Madsen, Marte Ustrup, Kristian S. Hansen, Peter S. Nyasulu, Ib C. Bygbjerg & Flemming Konradsen. (2014) Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi. Tropical Medicine & International Health 19:2, pages 177-185.
Crossref
Crossref
Maarten J Postma, Geert Top & Erik Buskens. (2013) Healthy aging through lifelong vaccination: a tale of two countries. Aging Health 9:6, pages 619-627.
Crossref
Crossref
Manuela Zlamy, Sabine Kofler, Dorothea Orth, Reinhard Würzner, Peter Heinz-Erian, Andrea Streng & Martina Prelog. (2013) The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infectious Diseases 13:1.
Crossref
Crossref
Stéphane Verguet, Shane Murphy, Benjamin Anderson, Kjell Arne Johansson, Roger Glass & Richard Rheingans. (2013) Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine 31:42, pages 4902-4910.
Crossref
Crossref
Karen Knipping, Johan Garssen & Belinda van’t Land. (2012) An evaluation of the inhibitory effects against rotavirus infection of edible plant extracts. Virology Journal 9:1.
Crossref
Crossref
Steven M. Lipson, Fatma S. Ozen, Laina Karthikeyan & Ronald E. Gordon. (2012) Effect of pH on Anti-Rotavirus Activity by Comestible Juices and Proanthocyanidins in a Cell-Free Assay System. Food and Environmental Virology 4:4, pages 168-178.
Crossref
Crossref
Greg L. Plosker. (2011) Rotavirus Vaccine RIX4414 (Rotarix™). PharmacoEconomics 29:11, pages 989-1009.
Crossref
Crossref